Reasons for lack of treatment in patients with locally advanced, unresectable or metastatic urothelial carcinoma-Reference-Cited by-同舟云学术

Reasons for lack of treatment in patients with locally advanced, unresectable or metastatic urothelial carcinoma

Published:2022-08-25 Issue:9 Volume:61 Page:1036-1042
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Omland Lise H.¹,Joensen Ulla N.²³,Toft Birgitte G.⁴,Lund Cecilia M.³⁵⁶,Lindberg Henriette⁷,Knudsen Mark B.⁸,Tolver Anders⁸^ORCID,Suetta Charlotte⁹,Pappot Helle¹

Affiliation:

1. Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Denmark

2. Department of Urology, Copenhagen University Hospital, Rigshospitalet, Denmark

3. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark

4. Department of Pathology, Copenhagen University Hospital, Rigshospitalet, Denmark

5. Department of Medicine, Copenhagen University Hospital, Herlev and Gentofte Hospital, Denmark

6. CopenAge, Copenhagen Center for Clinical Age Research, University of Copenhagen, Denmark

7. Department of Oncology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Denmark

8. Data Science Lab, Department of Mathematical Sciences, University of Copenhagen, Denmark

9. Department of Geriatric and Palliative Medicine, Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Denmark

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2022.2114378

Reference30 articles.

1. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

2. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

3. Urothelial carcinoma management in elderly or unfit patients

4. Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy

5. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A new era for bladder cancer: Enfortumab vedotin and pembrolizumab milestone approval;Tumori Journal;2023-12-23

2. Treatment patterns, survival, and healthcare utilisation and costs in patients with locally advanced and metastatic bladder cancer in Denmark 2015–2020;Acta Oncologica;2023-10-03